MASSDEVICE ON CALL — Massachusetts medical device giant Boston Scientific (NYSE:BSX) handed an unrestricted, 3-year $600,000 grant to the American Gastroenterological Assn. in support of ongoing research in GI technology research and education, the AGA announced yesterday.
The money will help fund 3 "high priority" areas of initiatives, including development of new technology, identification of unmet needs and formation of round-table discussions among leaders from clinical care and manufacturing, according to an AGA press release.
"The AGA, like Boston Scientific, has an unwavering commitment to critical research and education aimed at advancing science and patient care," Boston Scientific endoscopy president and senior vice president David Pierce said in prepared remarks. "We are a proud supporter of conferences like Digestive Disease Week and the annual AGA Technology Summit, and we are looking forward to expanding our relationship with the AGA to support gastroenterologist in an effort to improve patient outcomes and innovations in the field through digestive disease research."
Boston Scientific has been making strides and currying Wall Street favor over the past year, most recently with new clinical trial results showing the safety and efficacy of the company’s Alair bronchial thermoplasty system. BSX shares last week hit a new 4-year high of $11.67 apiece after the company released the results.
New "smart tooth" watches what you eat
Taiwanese researchers developed a "smart tooth" prototype, comprised of a removable artificial tooth, that keeps track of a person’s oral habits, using motion sensors that can tell with 94% accuracy whether a person is chewing, drinking, coughing or speaking, transmitting the data wirelessly to a computer application. The developers say the device could help doctors better track a patient’s eating habits, determine whether they’re grinding their teeth or monitor respiratory problems.
Read more
The Lancet pulls another Novartis study amid data fabrication concerns
Scientific journal The Lancet retracted Novartis AG’s (NYSE:NVS) Valsartan blood pressure drug study, originally published in July 2013. The journal’s editors said they "no longer having confidence in the published results" after discovering that there were concerns in Japan about the research as well as about the preceding Kyoto Heart Study, which also examined treatment with Valsartan.
Earlier this year a pair of former Novartis employees were pegged for involvement in a massive data fabrication scandal surrounding the Kyoto Heart Study, a post-market trial examining the company’s Valsartan drug in more than 3,0000 patients. Novartis has since wrapped up a 3rd-party investigation of its employees’ involvement, confirming their role in the analysis of the heart study results.
Read more
Minnesota touts lowest-cost Obamacare premiums
Officials from the Bay State claim that Minnesota’s Obamacare premiums will be the cheapest in the country with individual policies offered for just $90 per month. The insurance exchange, with nearly 80 plans for patients to chose from, is slated to open next month may be as much as 37% cheaper than plans offered by Obamacare exchanges in the 13 other states that have released rates so far.
Read more
At last, "personal" medical records for horses
California-based MMRGlobal announced this week that it’s the "1st out of the gate" with a system of personal health records targeted for horse care, an area that the company pegs as a multi-billion dollar market.
Read more
